Table 6 Cumulative clinical adverse events at long‐term follow‐up in patients treated with SES for protected and unprotected LMCA disease.
| Adverse events | Protected LMCA (n = 95) | Unprotected LMCA (n = 64) | p Value |
|---|---|---|---|
| All cause death (%) | 19.0 | 14.5 | 0.5 |
| Myocardial infarction (%) | 7.8 | 0 | 0.03 |
| All revascularisations (%) | 20.8 | 18.6 | 0.8 |
| PCI (%) | 20.8 | 15.3 | 0.1 |
| CABG (%) | 1.3 | 5.1 | 0.2 |
| Stroke (%) | 7.8 | 3.4 | 0.3 |
| Death/MI/stroke (%) | 24.6 | 14.8 | 0.1 |
| Death/MI/revasc (%) | 33.9 | 25.9 | 0.2 |
CABG, coronary artery bypass graft; LMCA, left main coronary artery; MI, myocardial infarction; PCI, percutaneous coronary intervention; SES, sirolimus‐eluting stent.